Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro.
about
Ultra-long acting insulin versus long-acting insulin for type 1 diabetes mellitusIntermediate acting versus long acting insulin for type 1 diabetes mellitusLong-acting insulin analogue versus another long-acting insulin analogue for type 2 diabetes mellitusLong acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitusLong-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitusConcepts and clinical use of ultra-long basal insulinLong-term safety and efficacy of insulin degludec in the management of type 2 diabetesInsulin therapy for the treatment of type 1 diabetes during pregnancyCurrent treatment options for type 2 diabetes mellitus in youth: today's realities and lessons from the TODAY studyPostprandial hyperglycemia and endothelial function in type 2 diabetes: focus on mitiglinideThe evolution of insulin glargine and its continuing contribution to diabetes careBiosynthetic engineered B28(K)-B29(P) human insulin monomer structure in water and in water/acetonitrile solutionsInsulin glargine 300 U/mL in the management of diabetes: clinical utility and patient perspectivesPharmacokinetics and pharmacodynamics of insulin glargine 300 U/mL in the treatment of diabetes and their clinical relevance.In Type 1 diabetic patients with good glycaemic control, blood glucose variability is lower during continuous subcutaneous insulin infusion than during multiple daily injections with insulin glargine.In vitro metabolic and mitogenic signaling of insulin glargine and its metabolitesInsulin glargine safety in pregnancy: a transplacental transfer study.Initiating insulin therapy in type 2 diabetic patients failing on oral hypoglycemic agents: basal or prandial insulin? The APOLLO trial and beyond.Distinct Prandial and Basal Glucose-Lowering Effects of Insulin Degludec/Insulin Aspart (IDegAsp) at Steady State in Subjects with Type 1 Diabetes MellitusEarly pharmacokinetic and pharmacodynamic effects of mixing lispro with glargine insulin: results of glucose clamp studies in youth with type 1 diabetes.Glucose supply and insulin demand dynamics of antidiabetic agents.Adding insulin glargine vs. NPH insulin to metformin results in a more efficient postprandial beta-cell protection in individuals with type 2 diabetesIdentifying and meeting the challenges of insulin therapy in type 2 diabetes.Insulin glargine 300 U/mL for basal insulin therapy in type 1 and type 2 diabetes mellitus.Dose-response effects of insulin glargine in type 2 diabetes.Comparison of continuous subcutaneous insulin infusion and insulin glargine-based multiple daily insulin aspart injections with preferential adjustment of basal insulin in patients with type 2 diabetes.Clinical experience with insulin glargine in type 1 diabetes.Glargine safety, diabetes and cancer.Metabolomics approach for analyzing the effects of exercise in subjects with type 1 diabetes mellitus.A randomized clinical trial comparing breakfast and bedtime administration of insulin glargine in children and adolescents with type 1 diabetes.Recent advances in treatment of youth with Type 1 diabetes: better care through technology.A review of the pharmacological properties of insulin degludec and their clinical relevance.Insulin glargine in the management of diabetes mellitus: an evidence-based assessment of its clinical efficacy and economic value.Insulin glargine: the first clinically useful extended-action insulin analogue.Systemically modeling the dynamics of plasma insulin in subcutaneous injection of insulin analogues for type 1 diabetes.A comparison of intermediate and long-acting insulins in people with type 2 diabetes starting insulin: an observational database study.Insulin analogues: have they changed insulin treatment and improved glycaemic control?Insulin glargine: a new basal insulin.Individualizing insulin management. Three practical cases, rules for regimen adjustment.The underuse of insulin therapy in North America.
P2860
Q24194881-F216B054-401F-483B-9234-15FC8C0897FAQ24241828-66C06E08-2647-4410-8222-68E468812A58Q24243694-1C6C9E76-EB04-424E-BFA4-3E7448F399AFQ24244721-371E2853-9B6F-49F3-ADA3-EB2848963EFBQ24245192-209F4FF9-F4BF-418E-AA0D-B805CB6CE58DQ26770354-B141D33C-3E6D-4D74-9EBB-E0CE75D6EDECQ26784381-8C615555-444E-4834-BAA0-F73EC7A61C7FQ26829977-4D8DE96A-A17F-41A0-A0F2-CD82E014DD4DQ26863463-29E480C0-696E-4BF3-A51E-ED4A41FB3E7DQ26865976-95F64B2D-17A0-4E22-8B91-E0CDBBFEB6D2Q26999454-6721D323-7B61-4201-9785-3FBAFF13D76BQ27683985-E6F7B8DB-3AC0-4803-A21B-7D5D3A154437Q28074690-47B5F701-28E7-4CF9-A8CA-3B3AE0833A12Q30248803-0FDDF51B-D234-4CB1-8A46-6608737187F3Q33321671-2BA53068-EB20-42B4-94AB-D7DEA700E576Q33537987-4E19CDC1-E63B-441E-952D-82CA9D92F79EQ33556840-76D34431-3F2C-4730-A7C6-931980B186F4Q33610830-04029792-3085-4724-9949-3AD9EED475D6Q33785190-995ABBE6-96AE-45C8-8829-29AB3A985686Q33804562-98C7BE57-B4EC-424C-9ABF-E46AC8662E8EQ33828255-4E57FB9C-53B5-4571-9D4E-2AE23426602AQ33853992-D1C9368B-47D0-41DB-A75A-1B48D11A9876Q33863413-78F58B01-A038-4C63-BB1B-CFC8A6D59D19Q33884391-521FAB0B-1A89-4B95-B5B6-0255D27A6A6DQ33932753-89DA4707-6F0B-43E0-A369-E1F93CA049AFQ34119580-CFCEF499-ED54-4EA1-A70E-EC8D9A75ED38Q34296834-0047FD7F-FB8A-4BB5-BF1A-2BA3A3F8F8A0Q34326924-B8F161DD-4DEF-4D8C-8684-EAB7342B2FD6Q34336580-AEAAF17E-4246-424B-AA97-0E8C048F1ECAQ34422997-BD33D9BB-466B-418B-8B67-5B1FF0CEF3E2Q34434731-881309F5-0E5E-4878-9BCF-DF35CF6B3DC2Q34436383-BD3F5F9A-242F-4B89-8ABD-50955573A1BBQ34449820-95422693-2EF0-4E55-BDDB-C9C27C371156Q34515529-72DAE520-639C-4B35-9CBE-B98951D8B92CQ34537345-E97028D8-DCB9-4800-9DD1-B67EF39BEB26Q34565168-C1686E90-EFFE-4C83-8DD6-113CF40628F7Q34580951-89392064-BDB0-47BA-9B7D-7840BC79A971Q34648626-1C51556A-71A9-4F44-8F9C-D4DF6C60B156Q34663249-DA6DE380-4F09-47AA-B2F8-3097BB0B1C43Q34906374-9514A651-4EE2-4C54-9BFE-65260FE84167
P2860
Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
2000年學術文章
@zh-hant
name
Pharmacokinetics and pharmacod ...... us infusion of insulin lispro.
@en
Pharmacokinetics and pharmacod ...... us infusion of insulin lispro.
@nl
type
label
Pharmacokinetics and pharmacod ...... us infusion of insulin lispro.
@en
Pharmacokinetics and pharmacod ...... us infusion of insulin lispro.
@nl
prefLabel
Pharmacokinetics and pharmacod ...... us infusion of insulin lispro.
@en
Pharmacokinetics and pharmacod ...... us infusion of insulin lispro.
@nl
P2093
P1433
P1476
Pharmacokinetics and pharmacod ...... us infusion of insulin lispro.
@en
P2093
Bartocci L
Brunetti P
Di Vincenzo A
Pampanelli S
Porcellati F
P304
P356
10.2337/DIABETES.49.12.2142
P407
P577
2000-12-01T00:00:00Z